The Potential Role of PD-1 x VEGF Bispecific Antibodies in the Management of Non-Small Cell Lung Cancer: Translating Emerging Evidence into Community Oncology Practice — Lecture

Faculty

Faculty

Julia Rotow

MD

Harvard Medical School, Boston, Massachusetts

Assistant Professor of Medicine

Lowe Center for Thoracic Oncology, Boston, Massachusetts

Clinical Director

Dana-Farber Cancer Institute, Boston, Massachusetts

Director of Clinical Research

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer.

LEARNING OBJECTIVES

• Appraise the scientific rationale for the development of bispecific antibodies directed at PD-1 x VEGF, and understand the mechanism of action of and similarities and differences among the various investigational agents in this class.
• Evaluate the documented efficacy of PD-1 x VEGF bispecific antibodies in combination with chemotherapy for patients with progressive EGFR-mutated metastatic non-small cell lung cancer (mNSCLC), and consider the potential role of these agents in treatment.
• Review published research findings with PD-1 x VEGF bispecific antibodies alone and in combination with chemotherapy as first-line therapy for patients with mNSCLC without actionable genomic alterations, and reflect on ongoing trials attempting to further validate the effectiveness of these strategies.
• Recognize the spectrum, frequency and severity of toxicities associated with PD-1 x VEGF bispecific antibodies, and appreciate management strategies available to facilitate the safe and effective use of these agents.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, review the slide presentation, complete the post-test with a score of 80% or better, and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Rotow — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, BioAtla, BioNTech SE, BlossomHill Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Caris Life Sciences, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Jazz Pharmaceuticals Inc, Johnson & Johnson, Merck, Merus, Novocure Inc, Nuvalent, Nuvation Bio Inc, ORIC Pharmaceuticals, Ottimo Pharma, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Summit Therapeutics, Takeda Pharmaceuticals USA Inc; Honoraria: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, BioAtla, BioNTech SE, Black Diamond Therapeutics Inc, BlossomHill Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Enliven Therapeutics, EpimAb Biotherapeutics, ImmunityBio, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, ORIC Pharmaceuticals, RedCloud Bio, Regeneron Pharmaceuticals Inc, Synthekine.

SURVEY PARTICIPANTS — Christina Baik, MD, MPH — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Natera Inc, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, UCB Japan; Research Funding (to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Avenzo Therapeutics, Black Diamond Therapeutics Inc, BlossomHill Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Nuvalent, Pfizer Inc, Summit Therapeutics, Syntrix Biosystems, SystImmune Inc; Nonrelevant Financial Relationships: Bristol Myers Squibb Foundation. Jonathan Goldman, MD — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pfizer Inc, Summit Therapeutics; Contracted Research: AbbVie Inc, Agenus Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, RayzeBio, Summit Therapeutics, Tango Therapeutics; Honoraria: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Summit Therapeutics; Research Grants: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, GSK, Summit Therapeutics, Tango Therapeutics. Paul K Paik, MD — Advisory Committees: EMD Serono Inc, Janssen Biotech Inc, Summit Therapeutics; Consulting Agreements: AbbVie Inc, EMD Serono Inc; Contracted Research: Bicara Therapeutics, EMD Serono Inc, Novartis, Nuvectis Pharma Inc, Summit Therapeutics. Antonio Passaro, MD, PhD has no relevant financial relationships to disclose. Zofia Piotrowska, MD, MHS — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Black Diamond Therapeutics Inc, BlossomHill Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Natera Inc, Nuvalent, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Summit Therapeutics, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tubulis; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BlossomHill Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Novartis, Nuvalent, Nuvectis Pharma Inc, Spectrum Pharmaceuticals Inc, SystImmune Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Summit Therapeutics.

Release date: October 16, 2026
Expiration date: October 16, 2027

Chen Z et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial. ASCO 2026;Abstract LBA4.

Chen Z et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): A randomised, double-blind, phase 3 trial. Lancet 2025;406(10515):2078-88. Abstract

Goldman JW et al. Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi. WCLC 2025;Abstract PL02.12.

Lu S et al. Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6). ESMO 2025;Abstract LBA4.

Lu S et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): Second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2023;11(7):624-36. Abstract

Peters S et al. Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC. ASCO 2026;Abstract 8513.

Wu L et al. Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO 2026;Abstract 8514.

Zhang L et al. Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment. SITC 2025;Abstract 1348.

Zhang L et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. ASCO 2024;Abstract 8508.

Zhou C et al. Phase 3 study of ivonescimab (AK112) vs. pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: Primary analysis of HARMONi-2. WCLC 2024;Abstract PL02.04.